Sofosbuvir and simeprevir combination therapy in the setting of liver transplantation and hemodialysis

R. B. Perumpail, R. J. Wong, L. D. Ha, E. A. Pham, U. Wang, H. Luong, R. Kumari, T. J. Daugherty, J. P. Higgins, Z. M. Younossi, W. R. Kim, J. S. Glenn, A. Ahmed

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

We report safety, tolerability, and 12-week sustained virologic response with half-standard dose sofosbuvir and standard-dose simeprevir combination therapy in a hepatitis C virus genotype 1a-infected liver transplant recipient on hemodialysis - uncharted territory for sofosbuvir-based therapy. The patient was a non-responder to prior treatment with pegylated interferon plus ribavirin. Sofosbuvir efficacy was maintained despite pill-splitting and administration of half-standard dose, 200 mg per day. No drug-drug interactions were noted with tacrolimus-based immunosuppression. Laboratory tests remained stable or improved during therapy. Our observation, if reproduced in a larger study, may lead to significant improvement in clinical outcomes and cost savings in this patient population.

Original languageEnglish (US)
Pages (from-to)275-278
Number of pages4
JournalTransplant Infectious Disease
Volume17
Issue number2
DOIs
StatePublished - Apr 1 2015
Externally publishedYes

Fingerprint

Liver Transplantation
Renal Dialysis
Cost Savings
Ribavirin
Tacrolimus
Therapeutics
Drug Interactions
Hepacivirus
Immunosuppression
Interferons
Genotype
Observation
Safety
Sofosbuvir
Simeprevir
Liver
Pharmaceutical Preparations
Population

Keywords

  • Direct-acting antivirals
  • Hemodialysis
  • Hepatitis C virus
  • Liver transplantation
  • Simeprevir
  • Sofosbuvir

ASJC Scopus subject areas

  • Transplantation
  • Infectious Diseases

Cite this

Perumpail, R. B., Wong, R. J., Ha, L. D., Pham, E. A., Wang, U., Luong, H., ... Ahmed, A. (2015). Sofosbuvir and simeprevir combination therapy in the setting of liver transplantation and hemodialysis. Transplant Infectious Disease, 17(2), 275-278. https://doi.org/10.1111/tid.12348

Sofosbuvir and simeprevir combination therapy in the setting of liver transplantation and hemodialysis. / Perumpail, R. B.; Wong, R. J.; Ha, L. D.; Pham, E. A.; Wang, U.; Luong, H.; Kumari, R.; Daugherty, T. J.; Higgins, J. P.; Younossi, Z. M.; Kim, W. R.; Glenn, J. S.; Ahmed, A.

In: Transplant Infectious Disease, Vol. 17, No. 2, 01.04.2015, p. 275-278.

Research output: Contribution to journalArticle

Perumpail, RB, Wong, RJ, Ha, LD, Pham, EA, Wang, U, Luong, H, Kumari, R, Daugherty, TJ, Higgins, JP, Younossi, ZM, Kim, WR, Glenn, JS & Ahmed, A 2015, 'Sofosbuvir and simeprevir combination therapy in the setting of liver transplantation and hemodialysis', Transplant Infectious Disease, vol. 17, no. 2, pp. 275-278. https://doi.org/10.1111/tid.12348
Perumpail, R. B. ; Wong, R. J. ; Ha, L. D. ; Pham, E. A. ; Wang, U. ; Luong, H. ; Kumari, R. ; Daugherty, T. J. ; Higgins, J. P. ; Younossi, Z. M. ; Kim, W. R. ; Glenn, J. S. ; Ahmed, A. / Sofosbuvir and simeprevir combination therapy in the setting of liver transplantation and hemodialysis. In: Transplant Infectious Disease. 2015 ; Vol. 17, No. 2. pp. 275-278.
@article{3fa246d187434f1ebbbd201ba42f93e4,
title = "Sofosbuvir and simeprevir combination therapy in the setting of liver transplantation and hemodialysis",
abstract = "We report safety, tolerability, and 12-week sustained virologic response with half-standard dose sofosbuvir and standard-dose simeprevir combination therapy in a hepatitis C virus genotype 1a-infected liver transplant recipient on hemodialysis - uncharted territory for sofosbuvir-based therapy. The patient was a non-responder to prior treatment with pegylated interferon plus ribavirin. Sofosbuvir efficacy was maintained despite pill-splitting and administration of half-standard dose, 200 mg per day. No drug-drug interactions were noted with tacrolimus-based immunosuppression. Laboratory tests remained stable or improved during therapy. Our observation, if reproduced in a larger study, may lead to significant improvement in clinical outcomes and cost savings in this patient population.",
keywords = "Direct-acting antivirals, Hemodialysis, Hepatitis C virus, Liver transplantation, Simeprevir, Sofosbuvir",
author = "Perumpail, {R. B.} and Wong, {R. J.} and Ha, {L. D.} and Pham, {E. A.} and U. Wang and H. Luong and R. Kumari and Daugherty, {T. J.} and Higgins, {J. P.} and Younossi, {Z. M.} and Kim, {W. R.} and Glenn, {J. S.} and A. Ahmed",
year = "2015",
month = "4",
day = "1",
doi = "10.1111/tid.12348",
language = "English (US)",
volume = "17",
pages = "275--278",
journal = "Transplant Infectious Disease",
issn = "1398-2273",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Sofosbuvir and simeprevir combination therapy in the setting of liver transplantation and hemodialysis

AU - Perumpail, R. B.

AU - Wong, R. J.

AU - Ha, L. D.

AU - Pham, E. A.

AU - Wang, U.

AU - Luong, H.

AU - Kumari, R.

AU - Daugherty, T. J.

AU - Higgins, J. P.

AU - Younossi, Z. M.

AU - Kim, W. R.

AU - Glenn, J. S.

AU - Ahmed, A.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - We report safety, tolerability, and 12-week sustained virologic response with half-standard dose sofosbuvir and standard-dose simeprevir combination therapy in a hepatitis C virus genotype 1a-infected liver transplant recipient on hemodialysis - uncharted territory for sofosbuvir-based therapy. The patient was a non-responder to prior treatment with pegylated interferon plus ribavirin. Sofosbuvir efficacy was maintained despite pill-splitting and administration of half-standard dose, 200 mg per day. No drug-drug interactions were noted with tacrolimus-based immunosuppression. Laboratory tests remained stable or improved during therapy. Our observation, if reproduced in a larger study, may lead to significant improvement in clinical outcomes and cost savings in this patient population.

AB - We report safety, tolerability, and 12-week sustained virologic response with half-standard dose sofosbuvir and standard-dose simeprevir combination therapy in a hepatitis C virus genotype 1a-infected liver transplant recipient on hemodialysis - uncharted territory for sofosbuvir-based therapy. The patient was a non-responder to prior treatment with pegylated interferon plus ribavirin. Sofosbuvir efficacy was maintained despite pill-splitting and administration of half-standard dose, 200 mg per day. No drug-drug interactions were noted with tacrolimus-based immunosuppression. Laboratory tests remained stable or improved during therapy. Our observation, if reproduced in a larger study, may lead to significant improvement in clinical outcomes and cost savings in this patient population.

KW - Direct-acting antivirals

KW - Hemodialysis

KW - Hepatitis C virus

KW - Liver transplantation

KW - Simeprevir

KW - Sofosbuvir

UR - http://www.scopus.com/inward/record.url?scp=84925357051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925357051&partnerID=8YFLogxK

U2 - 10.1111/tid.12348

DO - 10.1111/tid.12348

M3 - Article

AN - SCOPUS:84925357051

VL - 17

SP - 275

EP - 278

JO - Transplant Infectious Disease

JF - Transplant Infectious Disease

SN - 1398-2273

IS - 2

ER -